MCF Advisors’s aTyr Pharma ATYR Stock Holding History

MCF Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$836	Buy	1,400 +1,000	+250%	+$653	﹤0.01%	1325
2026 Q1	$312	Hold	400	–	–	﹤0.01%	1302
2025 Q4	$314	Hold	400	–	–	﹤0.01%	1104
2025 Q3	$289	Buy	+400	New	+$1.81K	﹤0.01%	930

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MCF Advisors's ATYR Position: Q2 2026 in Review

MCF Advisors increased its aTyr Pharma (ATYR) stake by 250% in Q2 2026, buying an estimated $653 and bringing the position to 1,400 shares worth $836. The position accounts for ﹤0.01% of the portfolio, ranked #1325.

MCF Advisors first reported a position in ATYR in Q3 2025 and has held it in 4 quarters since. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

MCF Advisors held 1,400 shares of aTyr Pharma worth $836 as of Q2 2026.
MCF Advisors bought 1,000 aTyr Pharma shares in Q2 2026, an estimated $653.
aTyr Pharma made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1325 holding.
MCF Advisors first reported a position in aTyr Pharma in Q3 2025 and has held it in 4 quarters since.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.